Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Cancer Causes Control. 2018 Sep 29;29(11):1081–1091. doi: 10.1007/s10552-018-1082-4

Table 4.

Crude and adjusted odds ratios for the association between epithelial ovarian cancer and benign gynecologic conditionsa stratified by oral contraceptive use.

Benign gynecologic condition Oral Contraceptive Use Cases(%) Control (%) Adjusted ORb 95% CI P interaction
Endometriosis 0.450
No OC Never Use 180 (95.7) 155 (98.1) 1.00 Referent
Yes 8 (4.3) 3 (1.9) 1.45 0.34–6.31
No OC Ever Use 371 (90.0) 564 (95.0) 1.00 Referent
Yes 41 (10.0) 30 (5.1) 1.92 1.13–3.24
PID 0.197
No OC Never Use 176 (93.6) 153 (96.8) 1.00 Referent
Yes 12 (6.4) 5 (3.2) 1.87 0.59–5.95
No OC Ever Use 380 (92.2) 564 (95.0) 1.00 Referent
Yes 32 (7.8) 30 (5.1) 1.31 0.76–2.26
Fibroid 0.703
No OC Never Use 118 (62.8) 116 (73.4) 1.00 Referent
Yes 70 (37.2) 42 (26.6) 1.23 0.73–2.06
No OC Ever Use 232 (56.3) 361 (60.8) 1.00 Referent
Yes 180 (43.7) 233 (39.2) 1.06 0.80–1.40
Ovarian Cyst 0.127
No OC Never Use 160 (85.1) 146 (92.4) 1.00 Referent
Yes 28 (14.9) 12 (7.6) 1.88 0.84–4.20
No OC Ever Use 360 (87.4) 522 (87.9) 1.00 Referent
Yes 52 (12.6) 72 (12.1) 1.00 0.66–1.51
# of gynecologic conditions 0.483
0 OC Never Use 104 (55.3) 108 (68.4) 1.00 Referent
1 57 (30.3) 39 (24.7) 1.38 0.81–2.33
2+ 27 (14.4) 11 (7.0) 2.36 1.07–5.19
p trend = 0.024

OR: odds ratio; CI: confidence interval; dz.: disease, PID: pelvic inflammatory disease

a

Diagnosis made >1 year before ovarian cancer diagnosis or interview.

b

Fully adjusted model – adjusted for age at diagnosis (cases)/interview (control), study site, marital status, education, BMI, parity, tubal ligation, family history of breast or ovarian cancer, talc use, endometriosis, fibroid, PID, ovarian cyst. OR for # of gynecologic conditions not adjusted for endometriosis, fibroid, PID, ovarian cyst.